Results 221 to 230 of about 940,318 (334)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACTCavin‐4 was identified as a potential autoantigen for immune‐mediated rippling muscle disease (iRMD). To validate this, we developed and tested various immunoassays, including a cell‐based assay (CBA), cavin‐4 recombinant protein ELISA, and multi‐peptide ELISA. Among 19 iRMD patients, all exhibited muscle rippling, and 13 had percussion‐induced
Reghann G. LaFrance‐Corey +13 more
wiley +1 more source
Hazardous substance USTs: RCRA Subtitle 1, Underground Storage Tanks. RCRA Information Brief
, 1994 Robert C. Dailey
openalex +1 more source
Unleashing the Power of Multiomics: Unraveling the Molecular Landscape of Peripheral Neuropathy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Peripheral neuropathies (PNs) affect over 20 million individuals in the United States, manifesting as a wide range of sensory, motor, and autonomic nerve symptoms. While various conditions such as diabetes, metabolic disorders, trauma, autoimmune disease, and chemotherapy‐induced neurotoxicity have been linked to PN, approximately one‐third of
Julie Choi +7 more
wiley +1 more source
Development of a Disease Model for Predicting Postoperative Delirium Using Combined Blood Biomarkers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Postoperative delirium, a common neurocognitive complication after surgery and anesthesia, requires early detection for potential intervention. Herein, we constructed a multidimensional postoperative delirium risk‐prediction model incorporating multiple demographic parameters and blood biomarkers to enhance prediction accuracy ...
Hengjun Wan +7 more
wiley +1 more source
Side-chain Liquid Crystalline Polyesters for Optical Information Storage
, 1996 P. S. Ramanujam +10 more
openalex +1 more source
Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier +8 more
wiley +1 more source
Universal Proteomic Signature After Exercise‐Induced Muscle Injury in Muscular Dystrophies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Several neuromuscular disorders (NMDs) are characterized by progressive muscle damage and are marked by the elevation of circulating muscle proteins from activity‐related injury. Despite a diverse array of genetic drivers, many NMDs share similar patterns of exercise intolerance and higher concentrations of muscle injury proteins ...
Mads G. Stemmerik +5 more
wiley +1 more source